Metronidazolo S.A.L.F. (Metronidazole)

Metronidazole is taken up by anaerobic microbes and reduced to reactive nitro radicals. These radicals damage DNA and inhibit nucleic acid synthesis, causing strand breakage and cell death. The process selectively affects anaerobic bacteria and certain protozoa while sparing aerobic cells.

The dosage of Metronidazolo S.A.L.F. is determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should set the appropriate regimen.

Safety data for metronidazole in pregnancy are limited, and the drug should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult a healthcare provider, as metronidazole can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazole belongs to the nitroimidazole class, offering activity against anaerobes and protozoa that many beta‑lactam antibiotics lack. Compared with broad‑spectrum agents, it provides targeted coverage for specific infections such as bacterial vaginosis and giardiasis, often with a lower risk of promoting resistant aerobic flora.

Metronidazolo S.A.L.F. should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Ensure the vial or ampoule is kept upright and sealed until use, and discard any product that appears discolored or cloudy.

The product is supplied for intravenous injection. It is administered by a qualified healthcare professional, typically as a slow infusion into a vein. The exact rate and duration depend on the prescribed dose and the clinical setting.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic toxicity, and neutropenia. Patients should be monitored for neurological symptoms, skin reactions, and liver function abnormalities during therapy.

Metronidazolo S.A.L.F. is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for individuals with severe hepatic impairment, a history of seizures, or those who are currently consuming alcohol.